IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Hovione signs agreement with Ligand Pharmaceuticals for Captisol technology

7:21 AM MDT | April 5, 2013 | Deepti Ramesh

Active pharmaceutical ingredients (APIs) producer Hovione (Loures, Portugal) says it has entered into a copromotion and collaboration agreement with Ligand Pharmaceuticals (La Jolla, CA) to provide Hovione’s customers access to Captisol technology. Captisol is a patent-protected, chemically modified cyclodextrin whose chemical structure was rationally designed to enable the creation of new products by significantly improving solubility, stability, bioavailability, and dosing of APIs. Captisol is currently used in six marketed products. Hovione offers...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa